Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib plus rituximab vs placebo plus rituximab in treatment-naïve follicular lymphoma
2023-507271-21-00Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial in follicular lymphoma (FL) comparing Ibrutinib + rituximab with Placebo + rituximab (2 arms). Primary endpoint: Progression-free survival. Started Feb 2024; status: completed.
02
Drugs
ibrutinib
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on 2023-507271-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507271-21-00.